Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease

Autoimmunity Reviews

Volumn 14, Issue 1, 2015, Pages 1-9

  Cantarini, Luca ^a   Lopalco, Giuseppe ^b   Caso, Francesco ^a,c   Costa, Luisa ^d   Iannone, Florenzo ^b   Lapadula, Giovanni ^b   Anelli, Maria Grazia ^b   Franceschini, Rossella ^a   Menicacci, Cristina ^a   Galeazzi, Mauro ^c   Selmi, Carlo ^e,f   Rigante, Donato ^g  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^g CATHOLIC UNIVERSITY   (Italy)

Author keywords

Anakinra; Beh et's disease; Canakinumab; Gevokizumab; Interleukin 1; Tuberculosis

Indexed keywords

CANAKINUMAB; GEVOKIZUMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

BEHCET DISEASE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYE DISEASE; GASTROINTESTINAL DISEASE; HUMAN; INFECTION RISK; MUSCULOSKELETAL DISEASE; MYCOBACTERIUM TUBERCULOSIS; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; PROTEIN TARGETING; REVIEW; SKIN INFECTION; TUBERCULOSIS; ANTAGONISTS AND INHIBITORS; BEHCET SYNDROME; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; MICROBIOLOGY; PATHOLOGY;

ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; TUBERCULOSIS;

EID: 84924272779     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.08.008     Document Type: Review

References (121)

1. Hatemi G., Yazici Y., Yazici H. Behçet's syndrome. Rheum Dis Clin North Am 2013, 39:245-261.
2. Yazici Y., Yurdakul S., Yazici H. Behçet's syndrome. Curr Rheumatol Rep 2010, 12:429-435.
3. Mendoza-Pinto C., García-Carrasco M., Jiménez-Hernández M., Jiménez Hernández C., Riebeling-Navarro C., Nava Zavala A., et al. Etiopathogenesis of Behçet's disease. Autoimmun Rev 2010, 9:241-245.
4. Verity D.H., Marr J.E., Ohno S., Wallace G.R., Stanford M.R. Behçet's disease, the silk road and HLA-B51: historical and geographical perspectives. Tissue Antigens 1999, 54:213-220.
5. Lehner T. The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behçet's disease. Int Rev Immunol 1997, 14:21-32.
6. Pineton de Chambrun M., Wechsler B., Geri G., Cacoub P., Saadoun D. New insights into the pathogenesis of Behçet's disease. Autoimmun Rev 2012, 11:687-698.
7. Direskeneli H. Behçet's disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis 2001, 60:996-1002.
8. Remmers E.F., Cosan F., Kirino Y., Ombrello M.J., Abaci N., Satorius C., et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat Genet 2010, 42:698-702.
9. Mizuki N., Meguro A., Ota M., Ohno S., Shiota T., Kawagoe T., et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. Nat Genet 2010, 42:703-706.
10. Zhou Z.Y., Chen S.L., Shen N., Lu Y. Cytokines and Behçet's disease. Autoimmun Rev 2012, 11:699-704.
11. Hamzaoui K., Hamza M., Ayed K. Production of TNF-alpha and IL-1 in active Behçet's disease. J Rheumatol 1990, 17:1428-1429.
12. Pay S., Erdem H., Pekel A., Simsek I., Musabak U., Sengul A., et al. Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Behçet's disease. Does interleukin-1β play a major role in Behçet's synovitis?. Rheumatol Int 2006, 27:608-613.
13. Karasneh J., Hajeer A.H., Barrett J., Ollier W.E., Thornhill M., Gul A. Association of specific interleukin 1 gene cluster polymorphisms with increased susceptibility for Behçet's disease. Rheumatology (Oxford) 2003, 42:860-864.
14. Akman A., Ekinci N.C., Kacaroglu H., Yavuzer U., Alpsoy E., Yegin O. Relationship between periodontal findings and specific polymorphisms of interleukin-1alpha and -1beta in Turkish patients with Behçet's disease. Arch Dermatol Res 2008, 300:19-26.
15. Castrichini M., Lazzerini P.E., Gamberucci A., Capecchi P.L., Franceschini R., Natale M., et al. The purinergic P2×7 receptor is expressed on monocytes in Behçet's disease and is modulated by TNF-α. Eur J Immunol 2014, 44:227-238.
16. Yazici H. The lumps and bumps of Behçet's syndrome. Autoimmun Rev 2004, 3(Suppl. 1):S53-S54.
17. Yazici H., Ugurlu S., Seyahi E. Behçet syndrome: is it one condition?. Clin Rev Allergy Immunol 2012, 43:275-280.
18. Gul A. Behçet's disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 2005, 4:81-83.
19. Cantarini L., Vitale A., Borri M., Galeazzi M., Franceschini R. Successful use of canakinumab in a patient with resistant Behçet's disease. Clin Exp Rheumatol 2012, 30(3 Suppl. 72):S115.
20. Cantarini L., Vitale A., Scalini P., Dinarello C.A., Rigante D., Franceschini R., et al. Anakinra treatment in drug-resistant Behçet's disease: a case series. Clin Rheumatol 2013, 10.1007/s10067-013-2443-8.
21. Vitale A., Rigante D., Caso F., Brizi M.G., Galeazzi M., Costa L., et al. Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behçet's disease: a case series. Dermatology 2014, 228:211-214.
22. Maestroni S., Di Corato P.R., Cumetti D., Chiara D.B., Ghidoni S., Prisacaru L., et al. Recurrent pericarditis: autoimmune or autoinflammatory?. Autoimmun Rev 2012, 12:60-65.
23. Rigante D. The fresco of autoinflammatory diseases from the pediatric perspective. Autoimmun Rev 2012, 11:348-356.
24. Cantarini L., Lucherini O.M., Muscari I., Frediani B., Galeazzi M., Brizi M.G., et al. Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives. Autoimmun Rev 2012, 12:38-43.
25. Muscari I., Iacoponi F., Cantarini L., Lucherini O.M., Simonini G., Brizi M.G., et al. The diagnostic evaluation of patients with potential adult-onset autoinflammatory disorders: our experience and review of the literature. Autoimmun Rev 2012, 12:10-13.
26. Cantarini L., Imazio M., Brucato A., Lucherini O.M., Galeazzi M. Innate versus acquired immune response in the pathogenesis of recurrent idiopathic pericarditis. Autoimmun Rev 2010, 9:436-440.
27. Caorsi R., Federici S., Gattorno M. Biologic drugs in autoinflammatory syndromes. Autoimmun Rev 2012, 12:81-86.
28. International Study Group for Behçet's Disease Criteria for diagnosis of Behçet's disease. Lancet 1990, 335:1078-1080.
29. Houman M.H., Kötter I., Olivieri I., Salvarani C., Sfikakis P.P., Siva A., et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008, 67:1656-1662.
30. Hatemi G., Silman A., Bang D., Bodaghi B., Chamberlain A.M., Gul A., et al. Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis 2009, 68:1528-1534.
31. Saadoun D., Bodaghi B., Bienvenu B., Wechsler B., Sene D., Trad S., et al. Biotherapies in inflammatory ocular disorders: interferons, immunoglobulins, monoclonal antibodies. Autoimmun Rev 2013, 12:774-783.
32. Papotto P.H., Marengo E.B., Sardinha L.R., Goldberg A.C., Rizzo L.V. Immunotherapeutic strategies in autoimmune uveitis. Autoimmun Rev 2014, 13:909-916.
33. Simonini G., Cantarini L., Bresci C., Lorusso M., Galeazzi M., Cimaz R. Current therapeutic approaches to autoimmune chronic uveitis in children. Autoimmun Rev 2010, 9:674-683.
34. Alpsoy E., Zouboulis C.C., Ehrlich G.E. Mucocutaneous lesions of Behçet's disease. Yonsei Med J 2007, 48:573-585.
35. Alpsoy E., Donmez L., Bacanli A., Apaydin C., Butun B. Review of the chronology of clinical manifestations in 60 patients with Behçet's disease. Dermatology 2003, 207:354-356.
36. Bang D., Hur W., Lee E.S., Lee S. Prognosis and clinical relevance of recurrent oral ulceration in Behçet's disease. J Dermatol 1995, 22:926-929.
37. Selmi C. Diagnosis and classification of autoimmune uveitis. Autoimmun Rev 2014, 13:591-594.
38. Mendes D., Correia M., Barbedo M., Vaio T., Mota M., Gonçalves O., et al. Behçet's disease a contemporary review. J Autoimmun 2009, 32:178-188.
39. Yazici H., Fresko I., Yurdakul S. Behçet's syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol 2007, 3:148-155.
40. Botsios C., Sfriso P., Furlan A., Punzi L., Dinarello C.A. Resistant Behçet disease responsive to anakinra. Ann Intern Med 2008, 149:284-286.
41. Choi I.J., Kim J.S., Cha S.D., Jung H.C., Park J.G., Song I.S., et al. Long-term clinical course and prognostic factors in intestinal Behçet's disease. Dis Colon Rectum 2000, 43:692-700.
42. Yurdakul S., Yazici H., Tüzün Y., Pazarli H., Yalçin B., Altaç M., et al. The arthritis of Behçet's disease: a prospective study. Ann Rheum Dis 1983, 42:505-515.
43. Caso F., Rigante D., Vitale A., Lucherini O.M., Cantarini L. Efficacy of anakinra in refractory Behçet's disease sacroiliitis. Clin Exp Rheumatol 2014, [Epub ahead of print].
44. Szekanecz Z., Szántó S., Szabó Z., Váncsa A., Szamosi S., Bodnár N., et al. Biologics - beyond the joints. Autoimmun Rev 2010, 9:820-824.
45. Atzeni F., Sarzi-Puttini P., Doria A., Boiardi L., Pipitone N., Salvarani C. Behçet's disease and cardiovascular involvement. Lupus 2005, 14:723-726.
46. Gurgun C., Ercan E., Ceyhan C., Yavuzgil O., Zoghi M., Aksu K., et al. Cardiovascular involvement in Behçet's disease. Jpn Heart J 2002, 43:389-398.
47. Hosaka A., Miyata T., Shigematsu H., Shigematsu K., Okamoto H., Ishii S., et al. Long-term outcome after surgical treatment of arterial lesions in Behçet disease. J Vasc Surg 2005, 42:116-121.
48. Tuzun H., Besirli K., Sayin A., Vural F.S., Hamuryudan V., Hizli N., et al. Management of aneurysms in Behçet's syndrome: an analysis of 24 patients. Surgery 1997, 121:150-156.
49. Nitecki S.S., Ofer A., Karram T., Schwartz H., Engel A., Hoffman A. Abdominal aortic aneurysm in Behçet's disease: new treatment options for an old and challenging problem. Isr Med Assoc J 2004, 6:152-155.
50. Park J.H., Chung J.W., Joh J.H., Song S.Y., Shin S.J., Chung K.S., et al. Aortic and arterial aneurysms in Behçet disease: management with stent-grafts - initial experience. Radiology 2001, 220:745-750.
51. Kwon Koo B., Shim W.H., Yoon Y.S., Kwon Lee B., Choi D., Jang Y., et al. Endovascular therapy combined with immunosuppressive treatment for pseudoaneurysms in patients with Behçet's disease. J Endovasc Ther 2003, 10:75-80.
52. Le Thi Huong D., Wechsler B., Papo T., Piette J.C., Bletry O., Vitoux J.M., et al. Arterial lesions in Behçet's disease. A study in 25 patients. J Rheumatol 1995, 22:2103-2113.
53. Akman-Demir G., Serdaroglu P., Tasçi B. Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. The Neuro-Behçet Study Group. Brain 1999, 122:2171-2182.
54. Pearce J.M.S. Neurological symptoms of Adamantiades-Behçet's syndrome. J Neurol Neurosurg Psychiatry 2006, 77:956-957.
55. Mohammed R.H., Nasef A., Kewan H.H., Al Shaar M. Vascular neurobehcet disease: correlation with current disease activity forum and systemic vascular involvement. Clin Rheumatol 2012, 31:1033-1040.
56. Al-Araji A., Kidd D.P. Neuro-Behçet's disease: epidemiology, clinical characteristics, and management. Lancet Neurol 2009, 8:192-204.
57. Dutra L.A., Gonçalves C.R., Braga-Neto P., Pedroso J.L., Gabbai A.A., Barsottini O.G., et al. Atypical manifestations in Brazilian patients with neuro-Behçet's disease. J Neurol 2012, 259:1159-1165.
58. Caso F., Costa L., Rigante D., Lucherini O.M., Caso P., Bascherini V., et al. Biological treatments in Behçet's disease: beyond anti-TNF therapy. Mediators Inflamm 2014, 2014:107421.
59. Dinarello C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011, 117:3720-3732.
60. Dinarello C.A., van der Meer J.W. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol 2013, 25:469-484.
61. Weber A., Wasiliew P., Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal Jan 19 2010, 3:cm1.
62. Moll M., Kuemmerle-Deschner J.B. Inflammasome and cytokine blocking strategies in autoinflammatory disorders. Clin Immunol 2013, 147:242-275.
63. Comarmond C., Wechsler B., Bodaghi B., Cacoub P., Saadoun D. Biotherapies in Behçet's disease. Autoimmun Rev 2014, 13:762-769.
64. Gül A., Tugal-Tutkun I., Dinarello C.A., Reznikov L., Esen B.A., Mirza A., et al. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study. Ann Rheum Dis 2012, 71:563-566.
65. Emmi G., Silvestri E., Cameli A.M., Bacherini D., Vannozzi L., Squatrito D., et al. Anakinra for resistant Behçet uveitis: why not?. Clin Exp Rheumatol 2013, 31(3 Suppl. 77):152-153.
66. Ugurlu S., Ucar D., Seyahi E., Hatemi G., Yurdakul S. Canakinumab in a patient with juvenile Behçet's syndrome with refractory eye disease. Ann Rheum Dis 2012, 71:1589-1591.
67. Alpsoy E. Behçet's disease: treatment of mucocutaneous lesions. Clin Exp Rheumatol 2005, 23:532-539.
68. Aikawa N.E., Gonçalves C., Silva C.A., Gonçalves C., Bonfá E., de Carvalho J.F. Late response to anti-TNF-α therapy in refractory mucocutaneous lesions of Behçet's disease. Rheumatol Int 2011, 31:1097-1099.
69. Cantarini L., Lopalco G., Vitale A., Coladonato L., Rigante D., Lucherini O.M., et al. Paradoxical mucocutaneous flare in a case of Behçet's disease treated with tocilizumab. Clin Rheumatol 2014, 10.1007/s10067-014-2589-z.
70. Bilginer Y., Ayaz N.A., Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet's disease. Clin Rheumatol 2010, 29:209-210.
71. Hatemi G., Seyahi E., Fresko I., Hamuryudan V. Behçet's syndrome: a critical digest of the recent literature. Clin Exp Rheumatol 2012, 30(3 Suppl. 72):S80-S89.
72. Pipitone N., Olivieri I., Padula A., D'angelo S., Nigro A., Zuccoli G., et al. Infliximab for the treatment of neuro-Behçet's disease: a case series and review of the literature. Arthritis Rheum 2008, 59:285-290.
73. Olivieri I., Cantini F., Castiglione F., Felice C., Gionchetti P., Orlando A., et al. Italian expert panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. Autoimmun Rev 2014, 13:822-830.
74. Borhani Haghighi A., Safari A. Tocilizumab may be a potential addition to our weapons against neuro-Behçet's disease. Med Hypotheses 2008, 71:156-157.
75. Shapiro L.S., Farrell J., Borhani Haghighi A. Tocilizumab treatment for neuro-Behçet's disease, the first report. Clin Neurol Neurosurg 2012, 114:297-298.
76. Urbaniak P., Hasler P., Kretzschmar S. Refractory neuro-Behçet treated by tocilizumab: a case report. Clin Exp Rheumatol 2012, 30(3 Suppl. 72):S73-S75.
77. Diamantopoulos A.P., Hatemi G. Lack of efficacy of tocilizumab in mucocutaneous Behçet's syndrome: report of two cases. Rheumatology (Oxford) 2013, 52:1923-1924.
78. Okada A.A., Goto H., Ohno S., Mochizuki M., Ocular Behçet's Disease Research Group Of Japan Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol 2012, 130:592-598.
79. Accorinti M., Pirraglia M.P., Paroli M.P., Priori R., Conti F., Pivetti-Pezzi P. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease. Jpn J Ophthalmol 2007, 51:191-196.
80. Perra D., Alba M.A., Callejas J.L., Mesquida M., Ríos-Fernández R., Adán A., et al. Adalimumab for the treatment of Behçet's disease: experience in 19 patients. Rheumatology (Oxford) 2012, 51:1825-1831.
81. Iwata S., Saito K., Yamaoka K., Tsujimura S., Nawata M., Hanami K., et al. Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease. Mod Rheumatol 2011, 21:184-191.
82. Joseph A., Raj D., Dua H.S., Powell P.T., Lanyon P.C., Powell R.J. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003, 110:1449-1453.
83. Borhani Haghighi A., Safari A., Nazarinia M.A., Habibagahi Z., Shenavandeh S. Infliximab for patients with neuro-Behçet's disease: case series and literature review. Clin Rheumatol 2011, 30:1007-1012.
84. Cantini F., Niccoli L., Goletti D. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries. J Rheumatol Suppl 2014, 91:56-64.
85. Zuñiga J., Torres-García D., Santos-Mendoza T., Rodriguez-Reyna T.S., Granados J., Yunis E.J. Cellular and humoral mechanisms involved in the control of tuberculosis. Clin Dev Immunol 2012, 2012:193923.
86. Sfikakis P.P., Markomichelakis N., Alpsoy E., Assaad-Khalil S., Bodaghi B., Gul A., et al. Anti-TNF therapy in the management of Behçet's disease - review and basis for recommendations. Rheumatology (Oxford) 2007, 46:736-741.
87. Campion G.V., Lebsack M.E., Lookabaugh J., Gordon G., Catalano M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum 1996, 39:1092-1101.
88. Bresnihan B., Alvaro-Gracia J.M., Cobby M., Doherty M., Domljan Z., Emery P., et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998, 41:2196-2204.
89. Jiang Y., Genant H.K., Watt I., Cobby M., Bresnihan B., Aitchison R., et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000, 43:1001-1009.
90. Cohen S., Hurd E., Cush J., Schiff M., Weinblatt M.E., Moreland L.W., et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:614-624.
91. Nuki G., Bresnihan B., Bear M.B., McCabe D., European Group Of Clinical Investigators Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:2838-2846.
92. Fleischmann R.M., Schechtman J., Bennett R., Handel M.L., Burmester G.R., Tesser J., et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003, 48:927-934.
93. Cohen S.B., Moreland L.W., Cush J.J., Greenwald M.W., Block S., Shergy W.J., et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004, 63:1062-1068.
94. Genovese M.C., Cohen S., Moreland L., Lium D., Robbins S., Newmark R., et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004, 50:1412-1419.
95. Schiff M.H., Di Vittorio G., Tesser J., Fleischmann R., Schechtman J., Hartman S., et al. The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. Arthritis Rheum 2004, 50:1752-1760.
96. den Broeder A.A., de Jong E., Franssen M.J., Jeurissen M.E., Flendrie M., van den Hoogen F.H. Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis 2006, 65:760-762.
97. Fleischmann R.M., Tesser J., Schiff M.H., Schechtman J., Burmester G.R., Bennett R., et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:1006-1012.
98. Karanikolas G., Charalambopoulos D., Vaiopoulos G., Andrianakos A., Rapti A., Karras D., et al. Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study. Rheumatology 2008, 47:1384-1388.
99. Le Loët X., Nordström D., Rodriguez M., Rubbert A., Sarzi-Puttini P., Wouters J.M., et al. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial. J Rheumatol 2008, 35:1538-1544.
100. Naumann L., Feist E., Natusch A., Langen S., Krause A., Buttgereit F., et al. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease. Ann Rheum Dis 2010, 69:466-467.
101. Lequerré T., Quartier P., Rosellini D., Alaoui F., De Bandt M., Mejjad O., et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008, 67:302-308.
102. Ohlsson V., Baildam E., Foster H., Jandial S., Pain C., Strike H., et al. Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). Rheumatology 2008, 47:555-556.
103. Ilowite N., Porras O., Reiff A., Rudge S., Punaro M., Martin A., et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 2009, 28:129-137.
104. Zeft A., Hollister R., LaFleur B., Sampath P., Soep J., McNally B., et al. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol 2009, 15:161-164.
105. Quartier P., Allantaz F., Cimaz R., Pillet P., Messiaen C., Bardin C., et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011, 70:747-754.
106. Nigrovic P.A., Mannion M., Prince F.H., Zeft A., Rabinovich C.E., van Rossum M.A., et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011, 63:545-555.
107. Brassard P., Kezouh A., Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006, 43:717-722.
108. Settas L.D., Tsimirikas G., Vosvotekas G., Triantafyllidou E., Nicolaides P. Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists (anakinra). J Clin Rheumatol 2007, 13:219-220.
109. Howard C., Noe A., Skerjanec A., Holzhauer B., Wernsing M., Ligueros-Saylan M., et al. Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies. Cardiovasc Diabetol 2014, 13:94.
110. Sundy J.S., Schumacher H.R., Kivitz A., Weinstein S.P., Wu R., King-Davis S., et al. Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study. J Rheumatol 2014, 8:1703-1711.
111. Ruperto N., Brunner H.I., Quartier P., Constantin T., Wulffraat N., Horneff G., et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012, 367:2396-2406.
112. Kuemmerle-Deschner J.B., Hachulla E., Cartwright R., Hawkins P.N., Tran T.A., Bader-Meunier B., et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 2011, 70:2095-2102.
113. Lovell D.J., Giannini E.H., Reiff A.O., Kimura Y., Li S., Hashkes P.J., et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum 2013, 65:2486-2496.
114. Hoffman H.M., Throne M.L., Amar N.J., Cartwright R.C., Kivitz A.J., Soo Y., et al. Long-term efficacy and safety profile of rilonacept in the treatment of cryopyrin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther 2012, 34:2091-2103.
115. Gillespie J., Mathews R., McDermott M.F. Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS). J Inflamm Res 2010, 3:1-8.
116. Goldbach-Mansky R., Shroff S.D., Wilson M., Snyder C., Plehn S., Barham B., et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 2008, 58:2432-2442.
117. Hoffman H.M., Throne M.L., Amar N.J., Sebai M., Kivitz A.J., Kavanaugh A., et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008, 58:2443-2452.
118. Cantini F., Niccoli L., Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl 2014, 91:47-55.
119. Botsios C. Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. Autoimmun Rev 2005, 4:162-170.
120. Ottenhoff T.H., Verreck F.A., Lichtenauer-Kaligis E.G., Hoeve M.A., Sanal O., van Dissel J.T. Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae. Nat Genet 2002, 32:97-105.
121. Song X., Krelin Y., Dvorkin T., Bjorkdahl O., Segal S., Dinarello C.A., et al. CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J Immunol 2005, 175:8200-8208.